Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment

NCT03358004 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT03358004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03358004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 2
Overall status
Terminated
Start date
June 14, 2017
Completion date
September 13, 2018
Enrollment
4 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer